Who will be the next Medtronic? What will be Minnesota's next breakthrough industry? James Walsh will provide the latest information and commentary on the people, companies and trends driving innovation in Minnesota. From visionary entrepreneurs to game changing technologies, this blog offers a window into the future of Minnesota's economy.

Medtronic wins approval for software to detect problems with other companies' leads

Posted by: James Walsh under Minnesota technology Updated: November 7, 2013 - 9:48 AM

Medtronic on Thursday announced U.S. Food and Drug Administration approval of its Lead Integrity Alert (LIA) software for use with non-Medtronic leads.

The software, which has been a standard feature on Medtronic devices since 2008, is now approved to report performance issues on Durata and Riata defibrillator leads made by St. Jude Medical and Endotak defibrillator leads made by Boston Scientific. Those leads must be connected to a Medtronic device.

Medtronic said LIA has shown the ability to detect lead issues in non-Medtronic leads at a greater rate than standard impedance monitoring alone. Impedance monitoring measures the electrical continuity of a lead four times per day.

For Durata and Riata leads, Medtronic said its software detected circuit issues six times more frequently than impedance monitoring.  For Endotak, circuit issues were detected four times more frequently, Medtronic said.

In the U.S., approximately 12,000 Medtronic LIA-enabled defibrillators are connected to non-Medtronic leads, the company said. That includes approximately 5,100 Endotak leads and 6,100 Riata and Durata leads.

Leads are considered the weak link in pacemaker and defibrillator therapy. The thin wires can fracture, disconnect from the heart and short-circuit. St. Jude's Riata lead was removed from the market in late 2010 after it was discovered that the lead's inner wires were coming through its outer insulation. A year later, the FDA recalled the device.

St. Jude Medical has repeatedly said it has seen no similar problems with its Durata leads, pointing to years of data and monitoring of thousands of patients.

ADVERTISEMENT

Connect with twitterConnect with facebookConnect with Google+Connect with PinterestConnect with PinterestConnect with RssfeedConnect with email newsletters

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT